Fundraising FoxARCH Venture Partners — 2025 Investments
17 investments dated 2025 · listed companies and verified rows first · show all
Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.
AI & Machine LearningBiotechHealthtechMedical Devices
Tassos Gianakakos(Co-Founder, Chief Executive Officer and Chair)inJay Edelberg, M.D., Ph.D.(Co-founder and Chief Medical Officer)inBob McDowell, Ph.D.(Co-Founder and Scientific Adviser)Leslie Leinwand, Ph.D.(Co-Founder)Beth McNally, M.D., Ph.D.(Co-Founder)
Co-investorsCatalio Capital Management, LPSequoia CapitalSequoia HeritageT. Rowe PriceVenrock
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)inRichard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Board seatSteve Gillis· per SEC Form D
Co-investorsInsight PartnersBroadview VenturesMedblueSolas BioVenturesPlatanus VenturesRev1 Ventures+1 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsAtlas VentureSanofi Ventures5AM Ventures
Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaSColumbus, US
Kent Thoelke(Founder)inJonathan Hirsch(Chief Strategy and Growth Officer)Jay Trepanier(Chief Financial Officer)inElijah Meerson(Chief Technology Officer)inMichelle Lee(Chief Operating Officer)in
Co-investorsGeneral CatalystGV (Google Ventures)Lux CapitalF-Prime CapitalJobsOhio VenturesMagnetic Ventures+2 more
.png)
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevityLos Angeles, US
Heather Christofk(Executive Officer)William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in
BoardCathy Friedman(Director)inDaniel Gil(CEO)
Co-investorsGV (Google Ventures)HAWKTAILVisionary VenturesYK Bioventures
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)inKatherine High(CEO)in
Co-investorsNovartis Venture FundBioGeneration VenturesF-Prime CapitalGV (Google Ventures)
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer; co-founder)in
Co-investorsF-Prime CapitalBain Capital Life SciencesDigitalis VenturesForbionMubadala Capital
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Board seatPaul Berns· per SEC Form D
Co-investorsBain Capital Life SciencesGV (Google Ventures)Solas BioVenturesViking GlobalAccess BiotechnologyMaverick Capital+3 more
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)
Board seatSteven Gillis· per SEC Form D
Co-investorsCatalio Capital Management, LPAlexandriaCatalio Capital Management
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardThong Le(Executive Officer, Director, Promoter)
Board seatSteven Gillis· per SEC Form D
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSAlexandriaWRF Capital
Rezo maps disease networks to find insights into disease biology for drug discovery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Nevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)
Board seatGeorge Scangos· per SEC Form D · $80.1M raise · filed Aug 2025
Co-investorsAndreessen HorowitzNorwest Venture PartnersHAWKTAILSR One Capital ManagementValkyrie Ventures Management, LlcSV Angel
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)
BoardAli Satvat(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalGV (Google Ventures)OrbiMedARC VENTURESCasdin CapitalExor+3 more
Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
BiotechDeep TechMedical Devices
Lex Johnson(Co-Founder and Chief Platform Officer)inRay Liu(Co-founder and Head of Synthetic Biology)Jeff Marrazzo(Founder)inSabah Oney(Chief Executive Officer)in
Co-investorsAlexandriaStanford University
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)in
Co-investorsDolby Family VenturesPfizer Venture InvestmentsSlater Technology FundPfizer Ventures
Paradigm Health is an Indiana-based hospice and palliative care provider offering community-based, holistic care to patients and support for their families and caregivers.
Digital HealthHealthtechWellness & Fitness
Jeff Jarecki(Founder & Chairman)in
Co-investorsCressey & CompanyHavencrest Capital ManagementF-Prime CapitalGeneral CatalystGV (Google Ventures)Lux Capital+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Octave Bioscience IncDispatch Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.